Page 372 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

350 PART III Therapeutic Modalities for the Cancer Patient

46. Vail DM, Kurzman ID, Glawe PC, et al.: STEALTH liposome- 67. Paoloni MC, Tandle A, Mazcko C, et al.: Launching a novel preclin-
encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant ical infrastructure: comparative oncology trials consortium directed
therapy for spontaneously arising osteosarcoma (OSA) in the dog: a therapeutic targeting of TNFalpha to cancer vasculature, PLoS One
VetBooks.ir randomized multicenter clinical trial, Cancer Chemother Pharmacol 68. Paoloni M, Lana S, Thamm D, et al.: The creation of the Compara-
4:e4972, 2009.
50:131–136, 2002.
47. London CA, Malpas PB, Wood-Follis SL, et al.: Multi-center, pla-
structure for a virtual laboratory, Vet J 185:88–89, 2010.
cebo-controlled, double-blind, randomized study of oral toceranib tive Oncology Trials Consortium Pharmacodynamic Core: infra-
phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the 69. Steensma DP, Kantarijian HM: Impact of cancer research bureau-
treatment of dogs with recurrent (either local or distant) mast cell cracy on innovation, costs and patient care, J Clin Oncol 32:376–
tumor following surgical excision, Clin Cancer Res 15:3856–3865, 378, 2014.
2009. 70. Freidlin B, Korn EL: Biomarker enrichment strategies: matching
48. Hahn KA, Ogilvie G, Rusk T, et al.: Masitinib is safe and effec- trial design to biomarker credentials, Nat Rev Clin Oncol 11:81–90,
tive for the treatment of canine mast cell tumors, J Vet Intern Med 2014.
22:1301–1309, 2008. 71. Sharma MR, Schilsky RL: Role of randomized phase III trials in an
49. Vail DM, von Euler H, Rusk AW, et al.: A randomized trial inves- era of effective targeted therapies, Nat Rev Clin Oncol 9:208–214,
tigating the efficacy and safety of water soluble micellar paclitaxel 2012.
(Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell 72. Chow SC: Adaptive clinical trial design, Annu Rev Med 65:
tumors in dogs, J Vet Intern Med 26:598–607, 2012. 405–415, 2014.
50. Gallo C, Perrone F: Clinical trial design in oncology: statistical 73. Menis J, Hasan B, Besse B: New clinical research strategies in tho-
power, Lancet Oncol 5:760–761, 2004. racic oncology: clinical trial design, adaptive, basket and umbrella
51. Fey MF: Clinical trial design in oncology: selection of patients, Lan- trials, new end-points and new evaluations of response, Eur Respir
cet Oncol 5:760, 2004. Rev 23:367–378, 2014.
52. Lonning PE: Strength and weakness of phase I to IV trials, with an 74. Sargent DJ, Korn EL: Sifting paradigms in cancer clinical trial
emphasis on translational aspects, Breast Cancer Res 10(suppl 4):S22, design, Nat Rev Clin Oncol 11:625–626, 2014.
2008. 75. Whitehead J: Stopping clinical trials by design, Nat Rev Drug Discov
53. Zon R, Meropol NJ, Catalano RB, et al.: American Society of Clini- 3:973–977, 2004.
cal Oncology Statement on minimum standards and exemplary 76. Betensky RA: Conditional power calculations for early acceptance of
attributes of clinical trial sites, J Clin Oncol 26:2562–2567, 2008. H0 embedded in sequential tests, Stat Med 16:465–477, 1997.
54. McLemore MR: The role of the data safety monitoring board: why 77. Lachin JM: A review of methods for futility stopping based on con-
was the Avastin phase III clinical trial stopped? Clin J Oncol Nurs ditional power, Stat Med 24:2747–2764, 2005.
10:153–154, 2006. 78. Berry DA: Decision analysis and Bayesian methods in clinical trials,
55. DiMasi JA, Grabowski HG: Economics of new oncology drug devel- Cancer Treat Res 75:125–154, 1995.
opment, J Clin Oncol 25:209–216, 2007. 79. Biswas S, Liu DD, Lee JJ, et al.: Bayesian clinical trials at the Uni-
56. Milne CP, Kaitin KI, Dimasi JA: Mandatory comparator trials for versity of Texas M. D. Anderson Cancer Center, Clin Trials 6:
therapeutically similar drugs: an assessment of the facts, Am J Ther 205–216, 2009.
14:231–234, 2007. 80. Rosner GL, Berry DA: A Bayesian group sequential design for mul-
57. Biotechnology Industry Organization (BIO): Late-stage clinical suc- tiple arm randomized clinical trials, Stat Med 14:381–394, 1995.
cess rates, New York, 2011, BIO CEO & Investor Conference. Febru- 81. Buzdar AU, Ibrahim NK, Francis D, et al.: Significantly higher
ary 15. pathologic complete remission rate after neoadjuvant therapy with
58. Rossen BR: FDA’s proposed regulations to expand access to inves- trastuzumab, paclitaxel, and epirubicin chemotherapy: results of
tigational drugs for treatment use: the status quo in the guise of a randomized trial in human epidermal growth factor receptor
reform, Food Drug Law J 64:183–223, 2009. 2-positive operable breast cancer, J Clin Oncol 23:3676–3685, 2005.
59. Karsdal MA, Henriksen K, Leeming DJ, et al.: Biochemical markers 82. Weishaar KM, Ehrhart EJ, Avery AC, et al.: Kit mutation and local-
and the FDA Critical Path: how biomarkers may contribute to the ization status as response predictors in mast cell tumors in dogs
understanding of pathophysiology and provide unique and neces- treated with prednisone and toceranib or vinblastine, J Vet Intern
sary tools for drug development, Biomarkers 14:181–202, 2009. Med 32:394–405, 2018.
60. Woodcock J, Woosley R: The FDA critical path initiative and its 83. Stadler W: Other paradigms: randomized discontinuation trial
influence on new drug development, Annu Rev Med 59:1–12, 2008. design, Cancer J 15:431–434, 2009.
61. Prowell TM, Theoret MR, Pazdur R: Seamless oncology-drug devel- 84. Stadler WM: The randomized discontinuation trial: a phase II design
opment, N Eng J Med 374:2001–2003, 2016. to assess growth-inhibitory agents, Mol Cancer Ther 6:1180–1185,
62. Hahn KA, Legendre AM, Shaw NG, et al.: Evaluation of 12- 2007.
and 24-month survival rates after treatment with masitinib 85. Rosner GL, Stadler W, Ratain MJ: Randomized discontinuation
in dogs with nonresectable mast cell tumors, Am J Vet Res 71: design: application to cytostatic antineoplastic agents, J Clin Oncol
1354–1361, 2010. 20:4478–4484, 2002.
63. Pryer NK, Lee LB, Zadovaskaya R, et al.: Proof of target for 86. Kindler T, Breitenbuecher F, Marx A, et al.: Sustained complete
SU11654: inhibition of KIT phosphorylation in canine mast cell hematologic remission after administration of the tyrosine kinase
tumors, Clin Cancer Res 9:5729–5734, 2003. inhibitor imatinib mesylate in a patient with refractory, secondary
64. Bergman PJ, McKnight J, Novosad A, et al.: Long-term survival of AML, Blood 101:2960–2962, 2003.
dogs with advanced malignant melanoma after DNA vaccination 87. McKeage K, Perry CM: Trastuzumab: a review of its use in the
with xenogeneic human tyrosinase: a phase I trial, Clin Cancer Res treatment of metastatic breast cancer overexpressing HER2, Drugs
9:1284–1290, 2003. 62:209–243, 2002.
65. Liao JC, Gregor P, Wolchok JD, et al.: Vaccination with human 88. Sawyers CL, Hochhaus A, Feldman E, et al.: Imatinib induces hema-
tyrosinase DNA induces antibody responses in dogs with advanced tologic and cytogenetic responses in patients with chronic myelog-
melanoma, Cancer Immun 6(8), 2006. enous leukemia in myeloid blast crisis: results of a phase II study,
66. Gordon I, Paoloni M, Mazcko C, et al.: The comparative oncol- Blood 99:3530–3539, 2002.
ogy trials consortium: using spontaneously occurring cancers in 89. London CA, Galli SJ, Yuuki T, et al.: Spontaneous canine mast cell
dogs to inform the cancer drug development pathway, PLoS Med tumors express tandem duplications in the proto-oncogene c-kit,
6:e1000161, 2009. Exp Hematol 27:689–697, 1999.